Please contact your health insurance company to confirm provider participation. For billing and insurance questions, please call our Billing Department at 210-358-3260.
As a physician-scientist specializing in pediatric congenital cardiac care, my passion extends beyond clinical practice to encompass educating patients and their families about the intricate physiological processes underlying congenital heart conditions. I believe a combination of research, excellent care, and holistic approach is fundamental to providing care that supports not just physical health, but overall well-being. My training began in Virginia for medical school, then I completed my residency at Virginia Commonwealth University, and last went on to complete a fellowship at Children’s National Hospital in Washington, DC.
I’m a pediatric critical care doctor at University Health and a physician-scientist who integrates biomedical engineering and medical research to improve the lives of critically ill children.
Philosophy of Care
My philosophy of care integrates the dual passions of scientific discovery and clinical excellence to improve the lives of children born with congenital heart defects. I believe that every child deserves the chance to live a full and healthy life, and our mission is to make that possibility a reality through innovative care and groundbreaking research.
My Favorite Thing about Medicine
As a physician-scientist, I am deeply invested in advancing our understanding of congenital cardiac diseases through rigorous research. I strive to foster an environment of curiosity, collaboration and hope to help patients, families, trainees, nurses and other providers.
Areas of Clinical Expertise
I have an active research program committed to decrease coagulation complications associated with critically illness with funding from the National Institutes of Health, American Heart Association, Children's Heart Foundation, and U.S. Army Institute of Surgical Research.
I also have an active research collaboration with the U.S. Army Medical Research and Development Command since 2013. Specifically, our lab evaluates novel anticoagulant therapies that reduce thromboembolic complications associated with life-saving devices such as extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass (CPB).